- Home
- LNTH
as 11-20-2024 4:00pm EST
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
| Founded: | 1956 | Country: | United States |
| Employees: | N/A | City: | NORTH BILLERICA |
| Market Cap: | 7.2B | IPO Year: | 2015 |
| Target Price: | $121.86 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 6.02 | EPS Growth: | 304.57 |
| 52 Week Low/High: | $50.20 - $126.89 | Next Earning Date: | 11-06-2024 |
| Revenue: | $1,496,799,000 | Revenue Growth: | 24.15% |
| Revenue Growth (this year): | 19.56% | Revenue Growth (next year): | 6.32% |
Stock Insider Trading Activity of Lantheus Holdings Inc. (LNTH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Marshall Robert J. Jr. | LNTH | CFO and Treasurer | Nov 15 '24 | Sell | $81.20 | 10,000 | $812,000.00 | 102,963 | |
| Blanchfield Paul | LNTH | President | Nov 14 '24 | Sell | $79.65 | 2,000 | $159,300.00 | 97,092 | |
| Heino Mary Anne | LNTH | Director | Nov 8 '24 | Sell | $87.90 | 11,487 | $1,001,217.84 | 447,436 |
Latest Lantheus Holdings Inc. News
LNTH Breaking Stock News: Dive into LNTH Ticker-Specific Updates for Smart Investing
Motley Fool
13 hours ago
Why Lantheus Holdings Stock Won Big on Wednesday
MT Newswires
a day ago
Lantheus Holdings Approves $250 Million Share Buyback Program
GlobeNewswire
a day ago
Lantheus Announces Share Repurchase Program
MT Newswires
2 days ago
Lantheus Holdings Insider Sold Shares Worth $812,000, According to a Recent SEC Filing
GlobeNewswire
8 days ago
Lantheus to Present at the Jefferies London Healthcare Conference
Simply Wall St.
8 days ago
Lantheus Holdings' (NASDAQ:LNTH) Promising Earnings May Rest On Soft Foundations
Argus Research
9 days ago
LNTH: Lowering target price to $89.00
GlobeNewswire
10 days ago
Lantheus Continues to Commend CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY’s Blockbuster Status for 2025
Compare LNTH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LNTH Lantheus Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.